FRA:KIN2

Kinross Gold Stock Dividends

*Your capital is at risk

23.74€

+0.110 (+0.466%)

At Close: Aug 10, 2026

KIN2.F Dividends Insights

KIN2.F pays dividends quarterly. Last paid amount was 0.0343€ at Jun 04, 2026. As of today, dividend yield (TTM) is 0.525%.

Dividend Score Premium

Avoid dividend cuts
with our Dividend Score
Start Free Trial

AI Analysis of KIN2.F

AI-Powered Dividend Insights

Built on AI-powered analysis of yield strength, recent news, payout trends, and 10-year dividend growth consistency.

Dividend Yield Range

The Dividend Yield Range is the range of values in which a stock’s dividend yield has fluctuated within a specified period, often a year. It represents the variation between the highest and lowest dividend yields observed during that time frame.

Dividend coming up for KIN2.F: Ex-dividend date (Thursday 20th August, 2026) is 8 days away. The dividend is 0.0300€.

AI Analysis of KIN2.F

AI-Powered Market Insights

New!

Dividend Analysis

Key Stats

Dividend Yield (TTM)	0.525%
Frequency	Quarterly
1Y Growth	33.30%
Payout Ratio	0
Amount Per Share	0.0343€
Next Ex-Dividend Date	Aug 20, 2026
Next Payment Date	Sep 03, 2026

Upcoming Dividend Payment

To receive the upcoming dividend from KIN2 the purchase should be done within the next 8 days.
Here's a simple guide on how to buy KIN2 stock.

KIN2 Dividend Payout History

To ensure a understanding of KIN2's dividend performance, consider examining the historical payout ratios and how they align with the company's earnings. Fluctuations in payout amounts may reflect changes in the company's dividend policy or earnings stability.

#	Declaration Date	Ex-Date	Pay Date	Amount	Yield
1	Aug 20, 2026	Aug 20, 2026	Sep 03, 2026	0.0347€	0.174%
2	May 21, 2026	May 21, 2026	Jun 04, 2026	0.0343€	0.132%
3	Mar 11, 2026	Mar 11, 2026	Mar 26, 2026	0.0344€	0.123%
4	Nov 26, 2025	Nov 26, 2025	Dec 10, 2025	0.0302€	0.137%
5	Aug 21, 2025	Aug 21, 2025	Sep 04, 2025	0.0257€	0.158%
6	May 29, 2025	May 29, 2025	Jun 12, 2025	0.0265€	0%
7	Mar 05, 2025	Mar 05, 2025	Mar 05, 2025	0.0287€	0%
8	Nov 28, 2024	Nov 28, 2024	Dec 12, 2024	0.0278€	0%
9	Nov 27, 2024	Nov 27, 2024	Dec 12, 2024	0.0283€	0%
10	Aug 22, 2024	Aug 22, 2024	Sep 06, 2024	0.0275€	0%

Requires Login

KIN2 Dividend Calculator

Dividend Calculator is designed to forecast the potential returns from KIN2 dividends based on your individual investment size or the number of shares you own. Simply enter your total investment amount to see the cumulative dividend payment you could receive over a specified period.
Read how to invest in KIN2 stock here.

FAQ

What factors can affect the amount of KIN2.F's dividend payments?

The amount of KIN2.F's dividends can fluctuate based on several factors, including the company's financial performance, earnings, cash flow, capital requirements, and overall market conditions. Changes in KIN2.F sector's trends, interest rate shifts, and the company's operational adjustments can also influence dividend decisions.

Can dividends from KIN2.F stock be automatically reinvested?

If KIN2.F offers a Dividend Reinvestment Plan (DRIP), shareholders may have the option to automatically reinvest dividends to purchase additional shares. Please check with your brokerage for the availability and details of such a plan. Here's an easy guide on how to buy KIN2.F stock.

How often does KIN2.F pay dividend?

Kinross Gold Corporation (KIN2.F) pays dividends quarterly. The most recent payout was on Jun 04, 2026. The upcoming dividend Ex Date is Aug 20, 2026, with an amount of 0.0347€.

How much does KIN2.F pays per share?

The last recorder (May 21, 2026) dividend per share was 0.0343€.

What is KIN2.F dividend growth rate?

Over the last year, Kinross Gold Corporation has witnessed growth rate of 33.30% . Looking back over the past 3 years, this growth rate has been 4.53%. Furthermore, examining the past 5 years, Kinross Gold Corporation has maintained an average Dividends Per Share Growth Rate of 2.69%.

ABOUT KINROSS GOLD CORPORATION

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
GPOR $158.45	6.03%	Aug 06
FCX $62.63	12.61%	Jul 31
BIIB $202.19	2.44%	Jul 24
TSCO $30.32	14.18%	Jul 23
S SW $43.71	8.88%	Jul 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by